SCHEMBL6790445

SCHEMBL6790445

CN(C)c1ccc(Br)c(N)c1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.42
KMT2A Q03164 1/20 0.42
CHEK1 O14757 1/20 0.35
NEK2 P51955 1/20 0.35
LIMK1 P53667 1/20 0.35
DYRK1A Q13627 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
MAPT P10636 3/20 0.34
APAF1 O14727 1/20 0.33
TDP2 O95551 1/20 0.33
NSD2 O96028 1/20 0.33
THRB P10828 1/20 0.33
RECQL P46063 1/20 0.33
GALK1 P51570 1/20 0.33
BLM P54132 1/20 0.33
CASP6 P55212 1/20 0.33
SAE1 Q9UBE0 1/20 0.33
UBA2 Q9UBT2 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MAPK1 P28482 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6787325 0.77 CHEK1 (0.36) GAAKMT2ACHEK1NEK2LIMK1
SCHEMBL27601700 0.75 GAA (0.35) GAAKMT2AMAPTMAPK1POLB
SCHEMBL2443752 0.74 GAA (0.46) GAAKMT2ACHEK1NEK2LIMK1
SCHEMBL19472050 0.71 CYP3A4 (0.38) GAAMAPTPOLBPTGER4
SCHEMBL18190317 0.70 GAA (0.43) GAAKMT2ACHEK1NEK2LIMK1
SCHEMBL23017166 0.69 PTGER4 (0.37) PTGER4
SCHEMBL6902104 0.68 GAA (0.30) GAAKMT2A
SCHEMBL5678498 0.67 PTGER4 (0.33) PTGER4
SCHEMBL27371626 0.67 PTGER4 (0.33) PTGER4
SCHEMBL17142269 0.67 MAPT (0.44) GAAKMT2AMAPTTHRBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6747051-B2 BLADDER UROGENITAL DISORDERS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-06-08 US disclosed
CN-1471514-A Novel M-amino-phenylimino-imidazolidone derivatives for treating urinary incontinence ���ָ��Ӣ��ķ�������Ϲ�˾ 2004-01-28 CN disclosed
US-20030158420-A1 m-Amino-phenylimino-imidazolidine derivatives for treaing urinary incontinence BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) 2003-08-21 US disclosed
US-6602897-B2 For example, 2-((2-bromo-3-chloro-5-dimethylamino-6-methylphenyl)imino)imid azolidine BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-08-05 US disclosed
EP-1328517-A2 NOVEL M-AMINO-PHENYLIMINO-IMIDAZOLIDINE DERIVATIVES FOR TREATING URINARY INCONTINENCE Boehringer Ingelheim Pharma KG (DE) 2003-07-23 EP disclosed
US-20020161031-A1 m-amino-phenylimino-imidazolidine derivatives for treating urinary incontinence BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-10-31 US disclosed
WO-2002032876-A2 NOVEL M-AMINO-PHENYLIMINO-IMIDAZOLIDINE DERIVATIVES FOR TREATING URINARY INCONTINENCE BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161031-A1 m-amino-phenylimino-imidazolidine derivatives for treating urinary incontinence RXFP1, RXFP3, PRMT1 GAA 4530/4885KMT2A 1573/4885CHEK1 3272/4885
US-20030158420-A1 m-Amino-phenylimino-imidazolidine derivatives for treaing urinary incontinence HRH2, RXFP3, AREG GAA 3387/4885KMT2A 1599/4885CHEK1 3338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.